Skip to main content

FDA Approvals

FDA Approvals, Payers' Guide

Welcome to the Ninth Annual Payers’ Guide to New FDA Approvals

FDA Approvals, Introduction, Payers' Guide

FDA Approvals in 2017 Represent a 21-Year High

Gary M. Owens, MD

FDA Approvals, Payers' Guide

FDA Approvals of Brand-Name Prescription Drugs in 2017

Payers' Guide, FDA Approvals

Xermelo (Telotristat Ethyl), First-in-Class Tryptophan Hydroxylase Inhibitor, Approved for Carcinoid Syndrome Diarrhea

Payers' Guide, FDA Approvals

Vyxeos (Daunorubicin and Cytarabine) Liposomal Combination First Treatment Approved for Patients with High-Risk Acute Myeloid Leukemia

Lisa A. Raedler, PhD, RPh

Payers' Guide, FDA Approvals

Tremfya (Guselkumab), First-in-Class IL-23 Blocker, Approved for the Treatment of Patients with Moderate-to-Severe Plaque Psoriasis

Payers' Guide, FDA Approvals

Simponi Aria (Golimumab), the Only Fully Human Anti–TNF-α Infused Therapy, Now Approved for Active Psoriatic Arthritis and for Active Ankylosing Spondylitis

Lisa A. Raedler, PhD, RPh

Payers' Guide, FDA Approvals

Siliq (Brodalumab) a New IL-17RA Antagonist Approved for Moderate-to-Severe Plaque Psoriasis

Payers' Guide, FDA Approvals

Shingrix (Zoster Vaccine Recombinant) a New Vaccine Approved for Herpes Zoster Prevention in Older Adults

Lisa A. Raedler, PhD, RPh

Payers' Guide, FDA Approvals

Nerlynx (Neratinib) First Extended Adjuvant Therapy Approved for HER2-Positive Breast Cancer

Page 27 of 53
Results 261 - 270 of 524